StockNews.AI
MRK
StockNews.AI
67 days

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

1. FDA approved Merck's KEYTRUDA for advanced head and neck cancer treatment.

FDA Approval
-0.13%Current Return
VS
-1.12%S&P 500
$81.8206/13 07:09 AM EDTEvent Start
$81.7106/16 06:05 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

The FDA approval of KEYTRUDA for HNSCC significantly expands Merck's therapeutic applications, likely increasing sales, similar to past approvals boosting stock prices.

How important is it?

Approval of KEYTRUDA aligns with Merck's growth strategy, indicating a potent market position in oncology treatments.

Why Long Term?

New approvals typically lead to sustained revenue growth; historical successes suggest long-term positive impact.

Related Companies

BMYAZNAMGN
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, con.

Related News